COMMUNIQUÉS West-GlobeNewswire

Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
22/04/2024
Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first two patients [...]
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
22/04/2024
Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 SAN MATEO, Calif., April 22, [...]
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
22/04/2024
ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
22/04/2024
PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, provided [...]
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
22/04/2024
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN (LX2006) to [...]
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
22/04/2024
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by [...]
Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials
22/04/2024
ANN ARBOR, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today what it considers to be a major milestone. The Company has completed [...]
BioCryst to Report First Quarter 2024 Financial Results on May 6
22/04/2024
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024 [...]
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
22/04/2024
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli [...]
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
22/04/2024
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company [...]
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
22/04/2024
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse 1 Approval is based on results from the PHASE 3 CARTITUDE- [...]
RadNet, Inc. Announces Date of its First Quarter 2024 Financial Results Conference Call
22/04/2024
LOS ANGELES, April 22, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer
22/04/2024
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer Feedback from FDA following Type B meeting enables Evexta Bio to move forward in clinical development of rupitasertib in [...]
Nexstim Receives NBS 6 System Order from Clinic in Florida, US
22/04/2024
Press release, Helsinki, 22 April 2024 at 11 AM (EEST) Nexstim Receives NBS 6 System Order from Clinic in Florida, US Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from a new [...]
Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement
22/04/2024
EDINBURGH, United Kingdom, April 22, 2024 (GLOBE NEWSWIRE) -- Kynos Therapeutics Ltd, a clinical-stage biotechnology company developing first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitors for acute [...]
Transactions in Connection with Share Buy-back Program Genmab
22/04/2024
Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. [...]
Orion Corporation: Managers’ transactions – Veli-Matti Mattila
22/04/2024
ORION CORPORATION MANAGERS’ TRANSACTIONS 22 APRIL 2024 at 9.45 EEST Orion Corporation: Managers’ transactions – Veli-Matti Mattila Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
22/04/2024
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli [...]
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
22/04/2024
Press Release Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue of €4.4 million (net revenue 1 €3.9 million) for first quarter 2024 Nicox Group cash of €9.1 million on [...]

Pages